These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 35138414)
1. [Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?]. Berliner C; Kesch C; Fendler WP; Eiber M; Maurer T Urologe A; 2022 Apr; 61(4):384-391. PubMed ID: 35138414 [TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging. Ferraro DA; Burger IA Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295 [TBL] [Abstract][Full Text] [Related]
3. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
4. Risk of metastatic disease on Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284 [TBL] [Abstract][Full Text] [Related]
5. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre. Haran C; McBean R; Parsons R; Wong D J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933 [TBL] [Abstract][Full Text] [Related]
6. Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: First-line imaging is afoot. Jiao J; Zhang J; Li Z; Wen W; Cui C; Zhang Q; Wang J; Qin W Cancer Lett; 2022 Nov; 548():215883. PubMed ID: 36027998 [TBL] [Abstract][Full Text] [Related]
7. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model. Alvim R; Nagar K; Das S; Lebdai S; Wong N; Somma A; Hughes C; Thomas J; Monette S; Scherz A; Kim K; Grimm J; Coleman JA Eur Urol Focus; 2021 Mar; 7(2):472-478. PubMed ID: 31227464 [TBL] [Abstract][Full Text] [Related]
8. Comparative study between Wong HS; Leung J; Bartholomeusz D; Sutherland P; Le H; Nottage M; Iankov I; Chang JH J Med Imaging Radiat Oncol; 2018 Dec; 62(6):816-822. PubMed ID: 30152050 [TBL] [Abstract][Full Text] [Related]
9. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328 [TBL] [Abstract][Full Text] [Related]
10. Utility of Ga Tarr GP; Kashyap P; Dixit DD; Willams AK; Koya MP; Lim R J Med Imaging Radiat Oncol; 2020 Feb; 64(1):78-86. PubMed ID: 31885207 [TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
12. How accurate is Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066 [TBL] [Abstract][Full Text] [Related]
13. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071 [TBL] [Abstract][Full Text] [Related]
14. Corfield J; Perera M; Bolton D; Lawrentschuk N World J Urol; 2018 Apr; 36(4):519-527. PubMed ID: 29344682 [TBL] [Abstract][Full Text] [Related]
15. A Multicenter Prospective Clinical Trial of McCarthy M; Francis R; Tang C; Watts J; Campbell A Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448 [TBL] [Abstract][Full Text] [Related]
16. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer. Afaq A; Bomanji J Br Med Bull; 2018 Dec; 128(1):37-48. PubMed ID: 30272121 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, Predictive Factors, and Prediction Nomograms for Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059 [TBL] [Abstract][Full Text] [Related]
18. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer. Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960 [TBL] [Abstract][Full Text] [Related]
19. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen ( Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951 [TBL] [Abstract][Full Text] [Related]
20. Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide. Young S; Liu W; Zukotynski K; Bauman G Expert Rev Anticancer Ther; 2021 Jun; 21(6):641-655. PubMed ID: 33476253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]